How does fingolimod (gilenya®) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?

Franz Fazekas, Ovidiu Bajenaru, Thomas Berger, Tanja Hojs Fabjan, Alenka Horvat Ledinek, Gábor Jakab, Samuel Komoly, Tetiana Kobys, Jörg Kraus, Egon Kurča, Theodoros Kyriakides, L'ubomír Lisý, Ivan Milanov, Tetyana Nehrych, Sergii Moskovko, Panayiotis Panayiotou, Saša Šega Jazbec, Larysa Sokolova, Radomír Taláb, Latchezar TraykovPeter Turčáni, Karl Vass, Norbert Vella, Nataliya Voloshyná, Eva Havrdová

Research output: Contribution to journalArticle

18 Citations (Scopus)
Original languageEnglish
Article number10
JournalFrontiers in Neurology
Volume4 MAY
DOIs
Publication statusPublished - 2013

Keywords

  • Algorithm
  • Expert opinion
  • Fingolimod
  • Multiple sclerosis
  • Treatment

Cite this

Fazekas, F., Bajenaru, O., Berger, T., Fabjan, T. H., Ledinek, A. H., Jakab, G., Komoly, S., Kobys, T., Kraus, J., Kurča, E., Kyriakides, T., Lisý, L., Milanov, I., Nehrych, T., Moskovko, S., Panayiotou, P., Jazbec, S. Š., Sokolova, L., Taláb, R., ... Havrdová, E. (2013). How does fingolimod (gilenya®) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis? Frontiers in Neurology, 4 MAY, [10]. https://doi.org/10.3389/fneur.2013.00010